InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - Management to host investor conference call today, March 12 th , at 8:30am ET - Miami, FL

Reports Fourth Quarter and Full Year 2024 Financial Results

to host investor conference call today, March 12th, at 8:30am ET

FL - March 12, 2025 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the

treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter

and full year ended December 31, 2024.

Business Highlights:

Slosman, CEO of InspireMD, commented: "2024 was a year of tremendous progress at InspireMD. We advanced CGuard Prime, our best-in-class

carotid implant, toward potential U.S. approval by submitting our PMA application to the FDA. We also initiated the CGUARDIANS II pivotal

study for its use in the large and growing TCAR market - an important step in expanding our development pipeline."

continue to see a clear path toward a potential CGuard Prime launch in the first half of 2025, pending approval. We are working closely

with the FDA to support the review process and look forward to bringing this innovative technology to patients in the U.S. I look forward

to key clinical, regulatory, and commercial milestones in the months ahead, particularly the potential U.S. approval and commercial launch

of CGuard Prime," Mr. Slosman concluded.

Results for the Fourth Quarter Ended December 31, 2024

the fourth quarter of 2024, total revenue increased by $188,000, or 10.7%, to $1,949,000, from $1,761,000 during the fourth quarter of

2023. This increase was predominantly driven by growth in new and existing markets.

profit for the fourth quarter of 2024 decreased by $36,000, or 7.1%, to $469,000, compared to a gross profit of $505,000 for the fourth

quarter of 2023. This decrease in gross profit resulted from an increase in cost of goods sold. This increase was primarily due to an

increase in material and labor costs, driven mainly to higher sales volume, and increased compensation expense for new and current employees.

The increase of cost of goods sold was offset by an increase of the revenues as described above.

operating expenses for the fourth quarter of 2024 were $9,836,000, an increase of $3,523,000, or 55.8% compared to $6,313,000 for the

fourth quarter of 2023. This increase was primarily due to increases in expenses related to salaries and share-based compensation as

we continue to expand our US personnel and sales force in anticipation of FDA approval. In addition, there was an increase of

expenses due to clinical, regulatory and development expenses related to our expected launch into the TCAR (transcarotid revascularization)

market and CGuard Prime product preparation expenses for the anticipated U.S. commercial launch, offset by a reduction in clinical trial

expenses associated with the C-GUARDIANS FDA Study as the one-year follow-up finalized in the second quarter of 2024.

income, net for the fourth quarter of 2024 was $252,000,

a decrease of $216,000 or 46.1% compared to $468,000 for the fourth quarter of 2023. This decrease was primarily due to less interest

income from investments in marketable securities and money market funds.

loss for the fourth quarter of 2024 totaled $9,174,000 or $0.19 per basic and diluted share, compared to a net loss of $5,405,000, or

$0.16 per basic and diluted share, for the same period in 2023.

of December 31, 2024, cash and cash equivalents and marketable securities were $34,637,000 compared to $39,023,000

as of December 31, 2023.

Results for the Full Year Ended December 31, 2024

the twelve months ended December 31, 2024, revenue increased by $804,000, or 13.0%, to $7,009,000, from $6,205,000 during the twelve

months ended December 31, 2023. This increase was driven by growth in existing and new markets.

profit for the twelve months ended December 31, 2024, decreased by 16.7%, or $301,000, to $1,506,000, compared to a gross profit of $1,807,000

for the same period in 2023. This decrease in gross profit resulted from an increase in cost of goods sold. This increase was primarily

due to an increase in material and labor costs, driven mainly to higher sales volume, and increased compensation expense for new and

current employees. In addition, there was an increase of other cost of goods sold related to miscellaneous expenses. The increase

of cost of goods sold was offset by an increase of the revenues as described above.

margin (gross profits as a percentage of revenue) decreased to 21.5% during the year ended December 31, 2024, from 29.1% during the year

ended December 31, 2023, driven by the factors mentioned above.

operating expenses for the twelve months ended December 31, 2024, were $35,009,000, an increase of $12,059,000, or 52.5% compared to

$22,950,000 for the twelve months ended December 31, 2023. This increase was primarily due to increases in expenses related to salaries

and share-based compensation as we expand our US personnel and sales force in anticipation of

FDA approval. In addition, an increase of expenses for clinical, regulatory and development expenses related to our expected

launch into the TCAR (transcarotid revascularization) market, CGuard Prime product preparation expenses for the anticipated U.S. commercial

launch, offset by a reduction in clinical trial expenses associated with the C-GUARDIANS FDA Study as the one-year follow-up finalized

in the second quarter of 2024.

the twelve months ended December 2024, was $1,557,000, an increase of $265,000 or 20.5% compared to $1,292,000 for the twelve months

ended December 31, 2023. The increase in financial income primarily resulted from an increase in interest income from investments

in marketable securities and money market funds.

loss for the twelve months ended December 31, 2024, totaled $32,005,000, or $0.76 per basic and diluted share, compared to a net loss

of $19,916,000, or $0.82 per basic and diluted share, for the twelve months ended December 31, 2023.

Call and Webcast Details

will host a conference call at 8:30 am ET today, March 12th, to review financial results and provide an update on corporate

developments. Following management's formal remarks, there will be a question-and-answer session.

March 12th at 8:30 a.m. ET

seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing

outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under

the ticker symbol NSPR.

routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements

regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding future events, future

financial performance, strategies, expectations, competitive environment and regulation, including potential FDA approval and potential

U.S. commercial launch. Such statements may be preceded by the words "intends," "may," "will," "plans,"

"expects," "anticipates," "projects," "predicts," "estimates," "aims,"

"believes," "hopes," "potential", "scheduled" or similar words. Forward-looking statements

are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties,

many of which are beyond the company's control, and cannot be predicted or quantified and consequently, actual results may differ

materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation,

risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial

doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of

our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the

future and such capital raising may be costly or difficult to obtain and could dilute out stockholders' ownership interests; market

acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical

trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability

to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect

our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality

standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may

not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition

in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical,

manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential

technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer

or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases

for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products;

our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful;

adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact

that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and

communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction;

the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable

economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed

information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the

Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and

its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's

web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result